Boehringer cancer drug effective in mid-stage trial
July 8 (Reuters) - German drugmaker Boehringer Ingelheim said its experimental blood cancer drug met its main goal in a mid-stage trial.
Data showed the cancer was not found in 31 percent of the patients treated with the drug volasertib along with a chemotherapy agent versus 13.3 percent of patients who were administered the chemotherapy alone.
The drug was studied in 87 older patients with untreated acute myeloid leukemia, a type of blood cancer. (Reporting by Shailesh Kuber; Editing by Saumyadeb Chakrabarty)